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Real-life patient experience: UK case presentation
A 49-year old woman presented in October 2007 with 
abdominal bloating, pain, and obvious ascites. After imaging 
data was obtained, in December 2007 the patient underwent 
total abdominal hysterectomy (TAH)/bilateral salpingo-
oophorec tomy (BSO) and debulking surgery to remove as 
much of the tumour as possible. After surgery the patient was 
diagnosed with serous ovarian adenocarcinoma, stage III C.
First-line chemotherapy was the recommended taxol/
carboplatin combination standard-of-care for 3 cycles, which 
ﬁ nished in March 2008. In June 2010 the patient relapsed 
and there was recurrence of disease, presenting as rapidly 
accumulating ascites.
The patient was rechallenged with platinum second-line; 
treatment was taxol/carboplatin for 6 cycles, which was 
completed in October 2010. The patient responded well to 
treatment with the ascites disappearing. The patient then 
agreed to participate in a phase II study investigating the 
CA-125 doubling time in patients with advanced disease 
treated with tamoxifen citrate [1].
In April 2011 there was recurrence of disease, and in August 
2011 the patient received trabectedin + PLD combination for 
5 cycles as fourth-line therapy. The patient achieved a good 
clinical response according to CA-125 measurement, and the 
chemotherapy was stopped given the good clinical status of 
the patient.
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The goal of recurrent ovarian cancer (ROC) treatment is no longer just palliation, but 
prolonging survival. This is usually through administering a new line of chemotherapy at each 
relapse. A novel treatment sequencing strategy to achieve this is through the intercalation of 
an effective non-platinum alternative, in between platinum-based therapies. Trabectedin in 
combination with pegylated liposomal doxorubicin (PLD) has been fully available privately 
in the UK since 2009 for treating patients with ROC. A single institution’s experience 
with the trabectedin + PLD combination, as a non-platinum/non-taxane alternative, to 
intercalate between platinum-based therapies is reported here. To date 6 patients have 
been successfully treated with trabectedin + PLD at Broomﬁ eld Hospital, Chelmsford, Essex. 
Here we describe a new, practice-changing treatment approach in a real-life case study of a 
heavily-treated patient with advanced ROC treated with trabectedin + PLD at fourth-line and 
then subsequently rechallenged at seventh-line; with treatment continuing until disease 
progression.
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In January 2012 the patient experienced disease progression 
and received subsequent treatment with gemcitabine/carbo-
platin/bevacizumab combination therapy for 6 cycles, plus 
bevacizumab 15 mg/kg every 3 weeks as maintenance therapy.
In June 2013 the patient experienced further disease pro-
gression and received taxol/carboplatin as weekly treatment 
for 6 cycles until January 2014, after which the patient’s 
disease was stable.
Fig. 1 – (a) CA-125 measurement following treatment with trabectedin + PLD. (b) CT images of the patient after 4 cycles of 
trabectedin + PLD showing improvement in symptoms (ascitic ﬂ uid). (c) CT images of the patient after 4 cycles of trabectedin 
+ PLD showing changes in lymph nodes.
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Disease recurrence occurred in March 2014, with ascites, 
para-aortic lymph node involvement, and peritoneal disease. 
The patient was subsequently re-challenged with trabectedin + 
PLD as seventh-line of chemotherapy. The patient responded 
clinically according to CA-125 measurement (Fig. 1a), and 
CT imaging showed a clinical response and improvement in 
symptoms (Fig. 1b,c).
The dose of trabectedin + PLD was adjusted for this patient 
due to grade 3 fatigue. The trabectedin dose was reduced from 
1.1 to 0.9 mg/m2, and PLD was reduced from 30 to 25 mg/m2. 
The management plan for this patient is to continue treatment 
with trabectedin + PLD until disease progression. The patient 
has ﬁ nished 11 cycles so far and is still in remission, and 
continues to do well.
In summary, this case study describes a new concept in the 
management of a ROC patient who has received 7 different 
lines of chemotherapy and has experienced recurrent disease. 
Trabectedin + PLD combination was effective as a non-platinum/
non-taxane alternative to intercalate between platinum-based 
therapies. In fact, trabectedin has been administered for 6 or 
more cycles in 52% of patients treated with the combination dose 
and schedule respectively. The combination regimen has been 
used for up to 21 cycles, and no cumulative toxicities have been 
observed in patients treated with multiple cycles [2]. So whilst 
doxorubicin is limited by its cumulative dose due to cardiotoxicity, 
trabectedin plus PLD can be used to disease progression. In the 
case study described here the patient is doing well, and will 
continue maintenance treatment with trabectedin + PLD, with 
repeat ECHO every 12 weeks, until disease progression.
Practical considerations with trabectedin plus PLD 
treatment
As with all cytotoxic regimens there are some practical 
considerations to treating patients with trabectedin + PLD. 
Trabectedin is administered every three weeks as a 3-hour 
intravenous (i.v.) infusion at a dose of 1.1 mg/m2, immediately 
after PLD 30 mg/m2, for the treatment of ovarian cancer (Fig. 2) 
[3]. The following steps must be taken when administering 
the combination [2]:
• All patients must receive corticosteroids e.g. 20 mg of 
dexamethasone i.v. 30 minutes prior to PLD
• 60 minute i.v. infusion of PLD 30 mg/m2. Intravenous adminis-
tration through a central venous line is strongly recommended
• 3-hour i.v. infusion of trabectedin 1.1 mg/m2, immediately 
after PLD, every 3 weeks through a central venous line
As with other cytotoxic regimens, monitoring of patients 
receiving trabectedin + PLD is recommended (Box 1).
The patient must satisfy the following criteria for initiation 
of treatment and prior to each re-treatment:
• Absolute neutrophil count (ANC) t1,500/mm3
• Platelet count t100,000/mm3
• Bilirubin d upper limit of normal (ULN)
• Alkaline phosphatase d2.5 × ULN (consider hepatic iso-
enzymes 5-nucleotidase or gamma glutamyl transpeptidase 
(GGT) to determine whether the elevation is of hepatic or 
osseous origin.
• Albumin t25 g/l.
• Alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) d2.5 × ULN
• Serum creatinine d1.5 mg/dL (d132.6 μmol/L) or creatinine 
clearance t60 mL/min
• Creatine phosphokinase (CPK) d2.5 × ULN
• Haemoglobin t9 g/dl
Otherwise treatment should be delayed and/or reduced for 
up to 3 weeks until the criteria are met, as highlighted in the 
case study above (Box 2).
Conclusions
The goal of ROC treatment is no longer just palliation, but 
prolonging survival. This is achieved by administering a new 
line of chemotherapy at each relapse. An additional approach 
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Fig. 2 – Schematic showing how to administer trabectedin + PLD.
Box 1 – Recommended blood tests for patients receiving 
trabectedin + PLD
• Neutrophils
• Platelets
• Bilirubin
• Alkaline phosphatase
• Transaminases ALT and AST
• CPK
• Haemoglobin
Test to be performed weekly during the ﬁ rst two cycles, and at 
least once between treatments in subsequent cycles.
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may be the administration of maintenance regimens. A single 
institution’s experience with trabectedin + PLD combination, 
as a non-platinum/non-taxane alternative to intercalate 
between platinum-based therapies is reported here. A real-
life case study is presented of a heavily-treated patient 
with advanced disease who was treated with trabectedin + 
PLD fourth-line and subsequently rechallenged at seventh-
line, who continues to do well on treatment. This case study 
demonstrates the utility of the combination at any line of 
relapse in ROC patients with advanced disease.
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Box 2 – Dose modiﬁ cation schedule for trabectedin + 
PLD [2]
 Trabectedin PLD*
Starting dose 1.1 mg/m2 30 mg/m2
First reduction 0.9 mg/m2 25 mg/m2
Second reduction 0.75 mg/m2 20 mg/m2
*See the PLD SmPC for more detailed information on PLD dose 
adjustments [4].
